| Title | Weight-Loss Drug Showdown: Mounjaro Overtakes Novo as Wegovy Launches in India |
|---|
| URL | https://www.easterneye.biz/weight-loss-novo-nordisk-mounjaro/ |
|---|
| Category | Media News --> Newspapers |
|---|
| Meta Keywords | Eli Lilly’s tirzepatide-based Mounjaro, offering once-weekly dosing, has quickly gained market dominance in India following its early‑2025 rollout |
|---|
| Meta Description | Eli Lilly’s tirzepatide-based Mounjaro, offering once-weekly dosing, has quickly gained market dominance in India following its early‑2025 rollout. In response, Novo Nordisk accelerated the launch of its rival semaglutide injection Wegovy in June. |
|---|
| Owner | easterneye |
|---|
| Description |
|---|
| Eli Lilly’s tirzepatide-based Mounjaro, offering once-weekly dosing, has quickly gained market dominance in India following its early‑2025 rollout. In response, Novo Nordisk accelerated the launch of its rival semaglutide injection Wegovy in June. Lilly’s offering outperformed Wegovy in clinical trials—showing ~20% average weight loss over 72 weeks versus Wegovy’s ~14%—and remains more affordable |
